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ABSTRACT
Hematopoietic stem cells derived from pluripotent stem cells could be used as an alternative to
bone marrow transplants. Deriving these has been a long-term goal for researchers. However, the
success of these efforts has been limited with the cells produced able to engraft in the bone mar-
row of recipient animals only in very low numbers. There is evidence that defects in the migratory
and homing capacity of the cells are due to mis-regulation of miRNA expression and are responsi-
ble for their failure to engraft. We compared the miRNA expression profile of hematopoietic pro-
genitors derived from pluripotent stem cells to those derived from bone marrow and found that
numerous miRNAs are too highly expressed in hematopoietic progenitors derived from pluripotent
stem cells, and that most of these are inhibitors of epithelial-mesenchymal transition or metastasis
(including miR-200b, miR-200c, miR-205, miR-148a, and miR-424). We hypothesize that the high
expression of these factors, which promote an adherent phenotype, may be causing the defect in
hematopoietic differentiation. However, inhibiting these miRNAs, individually or in multiplex, was
insufficient to improve hematopoietic differentiation in vitro, suggesting that other miRNAs and/
or genes may be involved in this process. STEM CELLS 2018;36:55–64
SIGNIFICANCE STATEMENT
Hematopoietic stem cell (HSC) transplants are an effective treatment for leukemia; however,
there is a shortage of appropriate donors. HSCs made from pluripotent stem cells could provide
a valuable alternative, but deriving these cells has proved difficult. This study shows that high
expression of a network of microRNAs may be a factor preventing this cell type from arising in
vitro. Although inhibiting them was insufficient to improve in vitro function due to redundancy
between microRNAs, this work provides insight into the mechanisms of differentiation which
may prove useful in future experiments.
INTRODUCTION
Hematopoietic stem cell (HSC) transplants are
an effective treatment for leukemia. The
patient is transplanted with HSCs from a
healthy donor, which then migrate-to and
engraft-in the bone marrow niche. Once there,
they resume their normal function: producing
replacement blood cells of all lineages through-
out the patient’s lifetime. The transplanted
cells must match the patient’s human leuko-
cyte antigen type or risk causing potentially
deadly graft-versus-host disease and unfortu-
nately there is a shortage of matching donors.
Generating HSCs from pluripotent stem
cells has been proposed as a potential
solution. However, attempts to do this in vitro
using human cells have not yielded clinically
viable results: in spite of recent advances
(reviewed by Slukvin [1]), the pluripotent stem
cell-derived hematopoietic progenitors (P-HPCs)
do not engraft in sufficient numbers in the
bone marrow niche when transplanted. The few
cells that do engraft fail to reconstitute an
entire hematopoietic system; they produce
mostly myeloid lineage progeny, and survive
only in the short or medium term [2–6],
whereas HSCs derived from donor marrow can
reconstitute an entire hematopoietic system
over serial transplants.
It is now possible to generate HSCs capa-
ble of engrafting and reconstituting the
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hematopoietic system at low frequency by ectopically express-
ing certain hematopoietic transcription factors [7, 8]. How-
ever, this technique is too risky to be used clinically due to
the oncogenic potential of these factors [9, 10].
Risue~no et al. achieved higher engraftment by injecting P-
HPCs directly into the bone marrow, rather than introducing
them to the bloodstream [2]. However, this is limited to the
femur into which they were injected and they did not colo-
nize the contra-lateral femur or the other hematopoietic
organs. The means that cells can engraft when they are intro-
duced directly into the niche but are unable to migrate to
other hematopoietic niches, unlike donor-derived HSCs. This
suggests that they are unable to gain a motile phenotype in
response to chemotactic signals.
In vitro systems for hematopoietic differentiation have
attempted to mimic embryonic development, either by expos-
ing the cells to a combination of hematopoietic cytokines or by
coculturing them with cells from the in vivo niche for hemato-
poietic development [11]. In the embryo, mesoderm gives rise
to hemogenic endothelium which in turn produces hematopoi-
etic cells [12]. The process by which the hemogenic endothelial
cells round-up and detach from the surrounding endothelium is
known as endothelial-hematopoietic transition (EHT), so-called
because of its similarity to epithelial-mesenchymal transition
(EMT) [13, 14]. Once free of the endothelium the cells migrate
to the fetal liver, and eventually to their adult niche in the bone
marrow [15]. Hematopoietic cells of various types arise from
the hemogenic endothelium throughout the vascular system
during embryonic development, but HSCs with self-renewal
potential arise in a short time-period and only from the floor of
the fetal aorta [16]. The EHT process has recently received a lot
of attention from groups attempting to make HSC from pluripo-
tent stem cells, because all blood cells arise via EHT both in vivo
and in vitro [1].
Inappropriate miRNA expression was suggested as a poten-
tial explanation for the failure of P-HPCs to engraft by Risue~no
et al. when they compared miRNA expression in HSCs to that in
P-HPCs and found that P-HPCs over-express a number of them.
miRNAs inhibit expression of their target genes by binding to
specific sequences on the untranslated region of the mRNA. A
miRNA can modulate the expression of multiple genes and they
are therefore key regulators of development.
Incorrect expression levels of miRNAs could have drastic
effects on the function of P-HPCs; hence we studied miRNA
expression in P-HPCs in comparison to HSCs to identify candi-
date miRNAs, whose expression could be manipulated to
result in successful P-HPC derivation. In this article, we pre-
sent a comprehensive profile of miRNA expression in P-HPCs.
We identify key miRNA candidates whose expression is mis-
regulated during human embryonic stem cell/human induced
pluripotent stem cell (hESC/hiPSC) differentiation, although
our data suggest that miRNA inhibition on its own is insuffi-
cient to improve hematopoietic differentiation in vitro,
highlighting the complexity of this process.
METHODS
Tissue Culture
hESC line H9 (WiCell, Madison, WI, USA) and hiPSC line SB-
Ad3 were cultured in STEMPRO medium (Thermo Fisher
Scientific, Cramlington, UK) on vitronectin (Stem cell technolo-
gies, Cambridge, UK) coated 6-well plates. The cells were
mechanically passaged at a ratio of 1:3 every 4 to 5 days or
when they reached 75% confluence.
Hematopoietic Differentiation
Experiments were done using the protocol described by Oliv-
ier et al. [17], modified by using only the first 12 days of the
protocol, that is, stopping before the cytokines for erythroid
specific differentiation are added.
Microarray Analysis
Two replicates of undifferentiated H9 hESC line and
CD311 CD341 KDR1 CD45- subpopulation from day 4 of dif-
ferentiation were subjected to RNA extraction and hybridiza-
tion to an Agilent G4470C-021827 array using the Agilent
protocol “miRNA Microarray System with miRNA Complete
Labeling and Hyb Kit,” Version 2.1. Human placenta cells were
used as an internal control. This data was compared with the
expression profile of human CD341 bone marrow cells
obtained from Gene Expression Omnibus, accession number
GSM595699. Expression data were normalized using quantile
normalization [18] and differential miRNA expression was esti-
mated using Limma package [19] from Bioconductor. Statisti-
cal significance (adjusted p values) was used to select the
miRNAs that were differentially expressed. Analysis of all the
mis-regulated miRNAs was carried out using information from
various databases including Targetscan [20] and miRbase [21]
as well as literature searches on NCBI.
Quantitative Reverse Transcription Polymerase Chain
Reaction (qRT-PCR)
RNA was extracted using the Reliaprep RNA cell miniprep sys-
tem (Promega, Madison, WI, USA). For qRT-PCR analysis of
miRNA, reverse transcription was done using the TaqMan
Micro-RNA RT Kit with a specific TaqMan Micro-RNA primer.
TaqMan Universal PCR Mastermix II and TaqMan MicroRNA
Assays were used for the qRT-PCR (all from Thermo Fisher Sci-
entific) RNU44 and RNU48 were chosen as internal controls.
CD341 human adult bone marrow and CD341 cord blood
cells (AllCells, Alameda, CA, USA) were used as positive con-
trols for qPCR analysis.
For the analysis of gene expression by qRT-PCR, 1 lg of
RNA was used in a 20 ll GoScript (Promega) reverse tran-
scription reaction, according to the manufacturer’s instruc-
tions. qRT-PCR was then performed using the SYBR Green
qRT-PCR kit (Life Technologies, Cramlington, UK). Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used as the
internal control. All qRT-PCR reactions were done at 10 ml in
triplicate on a 386 well plate in a TaqMan 7900 or a Quant-
Studio 7 (Thermo Fisher Scientific) machine. Primers were
designed using the NCBI Primer-BLAST tool and analyzed for
primer dimers and secondary structure formation using
Thermo Fisher’s multiple primer analyzer software. Primer
sequences are in Supporting Information Table 3. Significance
was determined by one-way ANOVA with three replicates.
Flow Cytometry and Cell Sorting
Cells were sorted on a FACSARIA (BD Biosciences, San Jose,
CA, USA) with markers CD34, CD45, CD41a, CD235a, (BD Bio-
sciences), and CD43 (Life Technologies). Cells were analyzed
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after miRNA inhibition on a LSRII (BD Biosciences) flow cytom-
etry machine using the same markers. Results were analyzed
using BD FACSDIVA software. At least 10,000 events were
acquired for each experiment.
Colony Forming Unit Assays
Six thousand unsorted cells were taken from differentiation
culture and transferred to a 3-ml aliquot of MethoCult media
and plated into two 10-mm cell culture dishes scored with 2-
mm grids. These were then incubated for 14 days. Colonies in
each dish were counted and scored based on their morphol-
ogy. Inhibitions were compared with control data using uni-
variate one-way analysis of covariance with effect of passage
number on numbers of hematopoietic progenitors as the
covariate (see Supporting Information Figs. 1, 2). p values are
calculated as Sidak corrected bootstrapped significance. Analy-
sis was performed using SPSS statistics software. Figures show
estimated marginal means.
Lipofection
Lipofectamine-RNAi complexes were prepared by diluting
20 pmol of mirVana miRNA inhibitor (Life technologies) or
control (mirVana miRNA inhibitor negative control, Life tech-
nologies, or Flourescein conjugate control, Santa Cruz biotech-
nology) in 50 ll Opti-MEM I Medium (Life technologies) and
6 ll of Lipofectamine RNAiMax (Life technologies) in 50ul
Opti-MEM I Medium. Both were incubated at room tempera-
ture for 5 minutes, then mixed and incubated at room tem-
perature for a further 20 minutes. For Multiplex reactions, 20
pmol of each inhibitor was used, while increasing the quantity
of lipofectamine to maintain the miRNA-inhibitor to lipofect-
amine ratio. The complexes were added to one well of a 12
well plate with 1 ml of differentiation medium at day 10 of
differentiation. Cells were analyzed after 48 hours.
Network Analysis
A list of all experimentally validated target genes of the
selected miRNAs was downloaded from http://mirtarbase.
mbc.nctu.edu.tw/ [22], a list of genes associated with EMT
was downloaded from http://dbemt.bioinfo-minzhao.org/
[23]. Cytoscape v3.5.1 [24] was used to generate and visualize
the genes which are both regulated by the chosen miRNAs
and which are validated regulators of EMT.
RESULTS
Hematopoietic Progenitors Derived from Pluripotent
Cells Over-Express EMT Suppressing miRNAs
A microarray approach was used to compare miRNA expres-
sion between undifferentiated pluripotent stem cells,
CD311 CD341 KDR1 CD45-P-HPCs derived from pluripotent
stem cells and CD341 bone marrow cells (Fig. 1A). The differ-
entially expressed miRNAs were grouped based on the pattern
of their expression (Fig. 1B, Supporting Information Table 1).
The flat-down group, that is, the group of miRNAs which
were expressed at high levels in both undifferentiated plurip-
otent stem cells and in P-HPCs, but at low levels in the bone
marrow hematopoietic progenitors contained 36 miRNAs. Of
these miRNAs the majority are described in the literature as
having functions as tumor or EMT suppressors (see Supporting
Information Table 2). Several of these miRNAs (miR-148a,
miR-200c and miR-200b, the miR-205, miR-34a, miR-424, miR-
9, miR-18b, and miR-34a) were chosen for validation by qRT-
PCR in differentiated cells derived from one hESC and one
hiPSC line. A more advanced differentiation protocol allowed
analysis of their expression in both early stage hemogenic
endothelial cells (day 4: CD311 CD341 KDR1 CD45-), and at
later stages of differentiation when committed hematopoietic
progenitors have undergone EHT (day 12: CD34low/–
CD431 CD451). The qRT-PCR results confirm that these miR-
NAs maintain their high expression throughout differentiation
from pluripotent stem cells to hematopoietic progenitors,
compared with bone marrow and cord blood CD341 cells,
which have low expression (Fig. 1C).
The continued high expression of these EMT-suppressing
miRNAs indicates that the miRNA regulation in the differentia-
tion process fails to recapitulate that of embryonic hematopoi-
etic differentiation. It is unsurprising that pluripotent stem cells
would have high levels of EMT suppressors as they are an epi-
thelial cell type, and bone marrow CD341 cells have low levels
of these miRNAs as they are of a migratory nature. That P-HPCs
express high levels of EMT suppressors suggests that despite
appearing to “bud” from the hemogenic endothelium as normal
blood cells do (see Fig. 1D), they have not fully undergone the
transformation from an adherent endothelial phenotype to a
motile hematopoietic phenotype. Failure to upregulate motility
related genes as well as EMT suppressors’ tendency to inhibit
self-renewal could explain the issues that have been reported in
transplant experiments using this cell type. By inhibiting these
EMT suppressing miRNAs, we hoped to improve the ability of
these hematopoietic cells to home to the niche.
Lipofection Is an Effective Short-Term Method of
Inhibiting miRNAs in P-HPCs
Five of the miRNAs which were demonstrated to maintain high
expression in P-HPCs but not HSCs were chosen for inhibition,
based on their well-defined and validated roles in the EMT pro-
cess: miR-148a, miR-200c, and miR-200b, the miR-205, miR-
424. Network analysis shows that between them, these miRNAs
regulate 72 out of 344 genes involved in EMT. Eight of these
genes are targets of more than one of these miRNAs, including
key EMT transcription factors ZEB1 and ZEB2 (Fig. 2)
We inhibited the miRNAs by introducing small complimen-
tary RNA molecules into the differentiating cells via lipofec-
tion. Although lipofection of inhibitors is a short-term method
of inhibiting miRNAs, it has the advantage of having no effect
on the genome, limiting the risk of oncogenic transformation.
miRNA inhibition was timed to coincide with the EHT of
definitive progenitors as this is when we predict EMT-
suppressing miRNAs will have the greatest negative effect on
hematopoiesis. Pilot experiments showed that miRNA inhibi-
tion is at peak effectiveness up to 48 hours after inhibition
(see Fig. 3A). CD431 CD341 cells begin to appear at day 6
but numbers peak between day 12 and day 16 and hemato-
poietic colony forming units peak at day 12 (Fig. 3B, 3C).
Therefore, miRNAs were inhibited at day 10, and the cells
analyzed at day 12. The inhibitions significantly reduced the
amount of their target miRNAs both individually and in com-
bination with other inhibitors (Fig. 3D).
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Inhibition of Highly-Expressed miRNAs Is Insufficient to
Improve Hematopoietic Function in Hematopoietic
Progenitors Derived from Pluripotent Cells
To test the effect of inhibition on hematopoietic differentia-
tion from pluripotent cells, we analyzed hematopoietic marker
expression, colony forming potential, and expression of key
miRNA target genes in day 12 differentiated cells. Hematopoi-
etic differentiation is controlled by numerous transcription
factors which are engaged in a stepwise manner but since we
are focusing on the EHT process we studied those transcrip-
tion factors specifically involved in that step. RUNX1 is essen-
tial for EHT and GATA2 and SCL are key upstream regulators
of this process [16, 25]. c-MYB is essential for definitive
hematopoiesis as well as being a direct target of miR-200c
[26, 27] and RORA has been shown as a transcription factor
able to promote EHT in hematopoietic cells derived in vitro.
ZEB1 and ZEB2 are essential regulators of EMT [28] as well as
direct targets of several of the inhibited miRNAs. If the miRNA
Figure 1. miRNA expression in pluripotent stem cells and bone marrow. (A): Microarray data showing the relationship between miRNA
expression in day 4 differentiated CD341 CD311 KDR1 CD45- (P-HPC), two replicates of undifferentiated hESC (hESC1 and hESC2) and
CD341 cells derived from human bone marrow. (B): Schematic graphs showing representative examples of estimated differential gene
expression from microarray data in different cell types outlined in 1(A). The distribution of normalized intensity values for each sample is dis-
played in the box plots, and the relative fluorescence of the individual miRNA is shown as a line graph. miRNAs have been sorted according
to the shape of the graph, for example, flat-down, flat-up, and so forth. For example, the flat down group miRNAs are expressed at similar
levels in the hESC lines and in the day 4 differentiated hESC cells but at a lower level in the CD341 bone marrow cells. (C): qRT-PCR valida-
tion of miRNA data in a hESC and an hiPSC cell line (H9 and SB-AD3, respectively), compared with CD341 cells derived from human cord
blood and bone marrow. Day 05 unsorted undifferentiated cells; day 45 CD311 CD341 KDR1 CD45- (hemogenic endothelium); day
125 CD34low/-CD41a-CD431 CD235a-CD451 (committed hematopoietic progenitors). Data are presented as mean6 SEM, n5 3. (D):
Representative micrograph of day 6 hESC-derived hematopoietic colonies. The bar represents 100 mm. Cells with endothelial morphology
can be seen around the edges of the colonies (green arrows) and some cells are beginning to round up and “bud off” the colonies (red
arrows), similar to in vivo hematopoietic cluster formation. Abbreviations: hESC, human embryonic stem cells; hiPSC, human induced plurip-
otent stem cell; P-HPCs, pluripotent stem cell-derived hematopoietic progenitor’s cells.
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inhibition was promoting EHT one would expect to see
increases in the expression of these genes.
Inhibition was effective for all the miRNAs, both individu-
ally and in combination. miR-205 inhibition alone inhibits
miR-205 transcript levels more than miR-205 in combination
with the other inhibitors, although miR-205 is still inhibited to
a significant degree in the combinatorial experiments. This is
an interesting result for which we do not have a complete
explanation but we do know that “crosstalk” occurs between
miRNA transcripts and that these miRNAs are involved in
complex feedback loops [29] with the genes that they regu-
late (see Fig. 2).
Although the expression of target miRNAs was robustly
inhibited, the effect on the expression of key EMT-associated
transcription factors which are targets of some or all of the
inhibited miRNAs was positive but fell short of being statisti-
cally significant (see Fig. 4); this may be due to the function
of miRNAs as modulators, which fine tune expression of mul-
tiple genes but do not have a large impact on any individual
gene. Neither did it have a significant effect on numbers of
committed hematopoietic progenitors (CD34low/-
CD431 CD451), (Fig. 5A). Few colony types were significantly
different in cells inhibited with any of the miRNAs, in fact the
only significant change which occurs in both cell lines is in
colony forming unit granulocyte, erythrocyte, monocyte,
megakaryocyte (CFU)-GEMM potential, which is significantly
decreased in both hESCs and hiPSCs (Fig. 5B). This is the
opposite result to what was anticipated as it indicates a
decrease in the fraction of multi-potent hematopoietic pro-
genitors (Fig. 5B). The results show that the hESC line
Figure 2. Highly expressed miRNAs and their involvement in endothelial-hematopoietic transition. A graphical representation of the
genes targeted by the five selected miRNAs. All experimentally validated targets of these miRNAs are shown, with arrows pointing from
the miRNAs to the genes which they regulate. Genes known to be involved in epithelial-mesenchymal transition are highlighted in yel-
low, red arrows point to these genes.
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produces more colonies overall, but variations in the differen-
tiation capacity of different pluripotent stem cell lines are an
established factor in stem cell research, and have been shown
to be due to epigenetic factors. For example, the chromatin
accessibility in the genes of the insulin-like growth factor 2
pathway affects the hematopoietic differentiation of hiPSC
and hESC lines [30].
DISCUSSION
We have demonstrated that EMT-suppressing miRNAs are
expressed at aberrantly high levels in P-HPCs, which likely
negatively affects their success in vivo. However, inhibiting
these miRNAs is insufficient to improve hematopoietic colony
formation in vitro so it is likely, though not guaranteed, that
Figure 3. Inhibition of miRNA expression in pluripotent stem cell-derived hematopoietic progenitor’s cells. (A): qRT-PCR expression analy-
sis of mir-200c in hESCs at 24, 48, 72, and 96 hours after lipofection. Data are shown as mean6 SEM, n5 3. (B): Schematic graph showing
numbers of hematopoietic colonies produced from an unsorted sample of hiPSC cells at day 12, day 16, and day 20 of differentiation. Data
are shown as mean6 SEM, n5 3. Representative micrographs of typical hematopoietic colonies are shown in Supporting Information
Figure 1. (C): Flow cytometry data showing the percentage of CD341 CD431 hematopoietic progenitors produced from hiPSCs at day 6,
day 12, day 16, and day 20. Data are shown as mean6 SEM, n5 3. (D): qRT-PCR data showing fold change in miRNA expression after inhibi-
tion of either a single miRNA or a combination of miR-424, miR-205, miR-148a, miR-200b, and miR-200c in the hiPSC and the hESC lines.
Fold change was calculated using the DDCT method. miRNAs were inhibited at day 10 of inhibition, and analyzed at day 12. Data are pre-
sented as fold-change derived from mean 2–DDCT values 6SEM, n5 3, *, p< .05. Abbreviations: BFU-E, burst forming unit-erythroid; CFU-E,
colony forming unit erythroid; CFU-G, colony forming unit granulocyte; CFU-M, colony forming unit macrophage; CFU-GM, colony forming
unit granulocyte-macrphage; CFU-GEMM, colony forming unit granulocyte-erythrocyte-monocyte-macrphage; hESC, human embryonic stem
cells; hiPSC, human induced pluripotent stem cell.
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Figure 4. Impact of miRNA downregulation on target gene expression. qRT-PCR data showing expression of key epithelial-mesenchymal
transition and hematopoiesis associated genes in hiPSCs and hESCs at day 12, 48 hours after inhibition. Data are shown as mean DDCT
values6 SEM, n5 3. Abbreviations: hESC, human embryonic stem cells; hiPSC, human induced pluripotent stem cell.
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Figure 5. Impacts of miRNA downregulation on hematopoietic differentiation of hESC and hiPSC. (A): Flow cytometry data: the percentage
of CD34low/-CD431 CD451 cells at day 12 of differentiation after miRNA inhibition. Data are shown as mean % of live cells6 SEM, n5 3.
(B): Schematic charts showing the impact of miRNA downregulation on various types of CFCs obtained from the differentiation of hESC and
hiPSC lines. Data are shown as mean 6SEM, n5 3, *, p< .05. Abbreviations: BFU-E, burst forming unit-erythroid; CFU-E, colony forming
unit erythroid; CFU-G, colony forming unit granulocyte; CFU-M, colony forming unit macrophage; CFU-GM, colony forming unit granulocyte-
macrphage; CFU-GEMM, colony forming unit granulocyte-erythrocyte-monocyte-macrphage; hESC, human embryonic stem cells; hiPSC,
human induced pluripotent stem cell.
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inhibition of these miRNAs would produce no functional
improvements in vivo.
There are several possible explanations for this negative
result. First, there is a great deal of redundancy between miR-
NAs suppressing the same EMT pathways, as can be seen in
the network analysis data, so inhibiting only five of them may
not have been sufficient. Second, miRNAs are modulators of
gene expression, with many only having a small effect on any
individual gene’s expression. These miRNAs are also part of a
network which contains stabilizing feedback loops, for exam-
ple the ZEB proteins targeted by the miR-200 cluster inhibit
the expression of the miR-200 cluster as well as several other
miRNAs [29]. This produces a compensatory effect, so that if
one EMT suppressor is inhibited others can be upregulated.
Sugimura et al. recently showed that it is possible to derive
functional HSCs from pluripotent stem cells; however, it
required them to ectopically express seven transcription fac-
tors and the final step of the process was carried out in the
in vivo bone marrow niche [31]. miRNAs are more subtle in
their effect, and this article shows the necessity of more dras-
tic interventions.
What is not clear is why attempting to induce HSC emer-
gence causes expression of these EMT-inhibiting miRNAs. HSC
generation is a unique developmental process in that it
involves self-renewing cells arising from the endothelium and
achieving the ability to migrate independently of contact with
the tissue of origin. This process must be precisely controlled
because in any other circumstances self-renewing cells moving
freely around the body is equivalent to metastasis. This is
reflected in the precise control of HSC emergence in the
embryo; although hematopoietic cells arise from blood vessels
throughout the developing embryo and extra-embryonic tis-
sues [32–35], hematopoietic cells capable of indefinite self-
renewal and hematopoietic reconstitution arise in a narrow
time frame and small anatomical area [16, 36]. The over-
expression of EMT-inhibiting miRNAs in differentiation cultures
can be explained by induction of a robust network of tumor
suppressors in response to self-renewing cells attempting to
leave their tissue of origin.
Given the similar expression patterns and functions of the
mis-expressed miRNAs it is possible that there is a common
regulatory element or system which is controlling their
expression. Further study will be needed to elucidate this
mechanism. It is clear that the current in vitro conditions in
which we differentiate P-HPCs are not effective in creating
HSCs, although we know it is possible to generate HSC from
pluripotent stem cells by introducing the undifferentiated cells
into a rodent model along with agents that promote hemato-
poiesis [37, 38], or by transplanting cells before day 3 of dif-
ferentiation and allowing them to develop in vivo [39]. This
shows that pluripotent stem cells have the potential to form
HSC but that this potential is lost very early in differentiation
using current protocols, suggesting that a more precise combi-
nation of signals is required, but although there has been
recent progress [34], the combination has not yet been
discovered.
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